Comorbidities and Long-Term Outcomes in a Cohort with Myasthenic Crisis: Experiences from a Tertiary Care Center.
Comorbidities
Muscle-specific tyrosine kinase
Myasthenia Gravis
Myasthenic crisis
Refractory Myasthenia Gravis
Thymoma
myasthenia gravis
Journal
Annals of Indian Academy of Neurology
ISSN: 0972-2327
Titre abrégé: Ann Indian Acad Neurol
Pays: India
ID NLM: 101273955
Informations de publication
Date de publication:
Historique:
received:
07
04
2019
revised:
26
06
2019
accepted:
30
06
2019
entrez:
19
11
2019
pubmed:
19
11
2019
medline:
19
11
2019
Statut:
ppublish
Résumé
There is scarce literature regarding the clinical course, comorbidities and long-term outcomes after myasthenic crisis (MC). The natural history of myasthenia gravis (MG) in this subset remains uncertain. The study included a cohort admitted with MC (2007-2017) in a tertiary care hospital. The comorbidities, outcomes after discharge, and prognostic factors were analyzed. Sixty-two patients (89 episodes of MC) were included. Demographic data was comparable between the early- (<50 years) and late-onset (≥50 years) groups. Comorbidities included stress cardiomyopathy (14.5%), arrhythmias (6.4%), neuropathy (17.7%), pancytopenia (12.9%), encephalopathy (11.2%), neuromyotonia (4.8%), myelopathy (3.2%), and myositis (3.2%). Pulmonary embolism ( A comprehensive treatment approach in MC will translate to good short- and long-term outcomes. The main cornerstones of therapy will include (1) Identification of refractory MG with the implementation of phenotype-based therapy; (2) Addressing comorbidities including cardiac autonomic neuropathy, bulbar weakness, phrenic dysfunction; and (3) Meticulous tumor surveillance.
Identifiants
pubmed: 31736571
doi: 10.4103/aian.AIAN_197_19
pii: AIAN-22-464
pmc: PMC6839309
doi:
Types de publication
Journal Article
Langues
eng
Pagination
464-471Informations de copyright
Copyright: © 2006 - 2019 Annals of Indian Academy of Neurology.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Neurology. 2000 Jul 12;55(1):16-23
pubmed: 10891897
Ann Cardiol Angeiol (Paris). 2011 Nov;60(5):290-5
pubmed: 21924700
BMJ Case Rep. 2009;2009:null
pubmed: 21686907
Curr Opin Neurol. 1998 Jun;11(3):233-4
pubmed: 9642541
Am J Emerg Med. 2013 Dec;31(12):1717-8
pubmed: 24161204
Ther Adv Neurol Disord. 2018 Jan 18;11:1756285617749134
pubmed: 29403543
Neurol India. 2005 Mar;53(1):37-40; discussion 40
pubmed: 15805653
Muscle Nerve. 1998 May;21(5):577-83
pubmed: 9572236
Yale J Biol Med. 2013 Jun 13;86(2):255-60
pubmed: 23766745
Eur J Neurol. 1998 Mar;5(2):137-142
pubmed: 10210824
J Neuroimmunol. 2014 Feb 15;267(1-2):111-2
pubmed: 24388224
Eur J Neurol. 2014;21(1):171-3
pubmed: 23398500
Rinsho Shinkeigaku. 2004 Mar;44(3):207-10
pubmed: 15233276
Muscle Nerve. 2008 Oct;38(4):1340-1
pubmed: 18785183
J Int Med Res. 2016 Dec;44(6):1524-1533
pubmed: 27856933
Arch Neurol. 2009 Nov;66(11):1407-9
pubmed: 19901174
Arch Neurol. 2008 Jul;65(7):929-33
pubmed: 18625860
Ann Intern Med. 2004 Dec 7;141(11):858-65
pubmed: 15583228
Neurohospitalist. 2011 Jan;1(1):16-22
pubmed: 23983833
Neurology. 2009 May 5;72(18):1548-54
pubmed: 19414721
Lancet Neurol. 2015 Oct;14(10):1023-36
pubmed: 26376969
Ann Indian Acad Neurol. 2013 Apr;16(2):203-7
pubmed: 23956564
Muscle Nerve. 1996 Apr;19(4):505-10
pubmed: 8622730
Mol Med. 2016 Mar;21(1):769-781
pubmed: 26562150
Muscle Nerve. 2011 Dec;44(6):990-3
pubmed: 22102473
Neurol Sci. 2014 Jul;35(7):1109-14
pubmed: 24497206
Ann N Y Acad Sci. 1981;377:670-7
pubmed: 6951491
Muscle Nerve. 2012 Sep;46(3):449-53
pubmed: 22907239
Autoimmunity. 2015;48(6):362-8
pubmed: 25915571
Int J Cardiol. 2005 Sep 1;103(3):335-7
pubmed: 16098399
Neurology. 1997 May;48(5):1253-60
pubmed: 9153452
QJM. 2009 Feb;102(2):97-107
pubmed: 19060020